Clinical Trial: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07484074) titled 'A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324' on March 09.

Brief Summary: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Study Start Date: Feb. 12, 2025

Study Type: INTERVENTIONAL

Condition: Diabetic Macular Edema (DME) Neovascular (Wet) Age-Related Macular Degeneration

Intervention: DRUG: Faricimab

Intravitreal Injection

DRUG: OLN324

Intravitreal Injection

Recruitment Status: COMPLETED

Sponsor: Ollin Biosciences, Inc.

Published by HT Digital Content Services with permission f...